<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7132016/results/search/test_trace/results.xml">
  <result pre="the COVID-19-related liver damage/dysfunction is due mainly to the viral" exact="infection" post="per se or other coexisting conditions, such as the"/>
  <result pre="focuses on the demographic and clinical characteristics, potential mechanisms, and" exact="treatment" post="options for COVID-19-related liver dysfunction. This review also describes"/>
  <result pre="review discusses the epidemiological characteristics, the potential mechanisms, and the" exact="treatment" post="options for liver dysfunction induced by COVID-19. Epidemiological characteristics"/>
  <result pre="covering COVID-19 patients, with a clear description of liver function" exact="tests" post="and results. All case reports without any data on"/>
  <result pre="All case reports without any data on patientsâ€™ liver function" exact="tests" post="were excluded. Finally, we included 14 eligible studies, including"/>
  <result pre="Main characteristics related to liver disease in patients with COVID-19" exact="infection" post="in different Chinese regions based on a series of"/>
  <result pre="load of COVID-19 in exposed patients in Wuhan, where the" exact="infection" post="began and was concentrated in a greater proportion of"/>
  <result pre="higher than in hepatocytes and these findings suggest that SARS-CoV-2" exact="infection" post="might also cause bile duct epithelial cell damage.21,22 However,"/>
  <result pre="worldwide.25 In addition, although there is currently no targeted antiviral" exact="treatment" post="for COVID-19, many infected patients have also been treated"/>
  <result pre="syndrome Although many COVID-19 patients were not too unwell, this" exact="infection" post="in some patients has resulted in sudden deterioration, ending"/>
  <result pre="options for COVID-19-related liver dysfunction Presently, there is no specific" exact="treatment" post="for COVID-19 infection.31 Therefore, the cornerstone of COVID-19 management"/>
  <result pre="COVID-19 infection.31 Therefore, the cornerstone of COVID-19 management is patient" exact="isolation" post="and supportive medical care where necessary, including pulmonary ventilation"/>
  <result pre="the ACE/Ang II/AT1R pathway could be potential pathways for the" exact="treatment" post="of COVID-19. For SARS-CoV-2-infected patients, both ACE-inhibitors and angiotensin-II-receptor"/>
  <result pre="in regions where a smaller proportion of cases of COVID-19" exact="infection" post="in the population have occurred. (2) The proportion of"/>
  <result pre="the front-line medical staff should pay attention to liver function" exact="tests" post="in patients infected with COVID-19. For those patients with"/>
  <result pre="pneumonia in Wuhan, China: a descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 6ZhangYHLinDJXiaoMFWangJCWeiYLeiZXet al.[2019-novel coronavirus" exact="infection" post="in a three-month-old baby]Zhonghua Er Ke Za Zhi202058E00610.3760/cma.j.issn.0578-1310.2020.000632043842 7ChenFLiuZSZhangFRXiongRHChenYChengXFet"/>
  <result pre="Ke Za Zhi202058E00510.3760/cma.j.issn.0578-1310.2020.000532045966 8CaiJHWangXSGeYLXiaAMChangHLTianHet al.[First case of 2019 novel coronavirus" exact="infection" post="in children in Shanghai]Zhonghua Er Ke Za Zhi202058868710.3760/cma.j.issn.0578-1310.2020.02.00232102141 9HolshueMLDeBoltCLindquistSLofyKHWiesmanJBruceHet"/>
  <result pre="18ChenHGuoJWangCLuoFYuXZhangWet al.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="key mediator of hepatic ischemia-reperfusion injuryNat Med201824738310.1038/nm.445129227475 31ZhangZLiXZhangWShiZLZhengZWangTClinical features and" exact="treatment" post="of 2019-nCov pneumonia patients in Wuhan: report of a"/>
  <result pre="natural compounds for preventing 2019-nCoV infectionPreprints20202020010358(v3)10.20944/preprints202001.0358.v3 37LiJYCaoHYLiuPChengGHSunMYGlycyrrhizic acid in the" exact="treatment" post="of liver diseases: literature reviewBiomed Res Int2014201487213910.1155/2014/87213924963489 38YanRZhangYLiYXiaLZhouQStructure of"/>
 </snippets>
</snippetsTree>
